TAG:
whole slide imaging
Business Advantages From Whole Slide Imaging
By Robert Michel | From the Volume XVII No. 5 – March 29, 2010 Issue
CEO SUMMARY: Whole slide imaging (WSI) is a niche product today, but it offers the potential to redefine the practice of pathology. That’s the opinion of pathologists presenting at a digital pathology workshop last month. One pathologist explained how WSI significantly improves collabor…
Multispectral Tests Use “Smart” Systems To Analyze Tissue
By Robert Michel | From the Volume XVII No. 3 – February 15, 2010 Issue
CEO Summary: Pathologists at the Hospital of the University of Pennsylvania are using a new system that combines image analysis software and algorithms to evaluate images containing numerous stains and biomarkers. Pathologists teach the system to identify tumor cells and distinguish them …
FDA Advisory Panel Convenes To Assess Whole Slide Imaging
By Robert Michel | From the Volume XVI No. 15 – November 02, 2009 Issue
Editor’s Note: Guest writer Martin Perry attended the FDA’s advisory panel on digital pathology conducted earlier this month. He is CEO of The Perry Group and has extensive experience in imaging and healthcare. He offers his insights from the FDA proceedings on digital pathology imaging….
GE, UPMC Create Company for Digital Path Imaging
By Robert Michel | From the Volume XV No. 8 – June 16, 2008 Issue
CEO SUMMARY: It’s a new joint venture with the potential to transform surgical pathology. General Electric Healthcare has extensive experience at supporting physicians’ work flow with digitized imaging systems, plus ample experience with molecular bio-markers. The University of Pittsb…
Free of IMPATH, Tamtron Ready For A New Future
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
CEO SUMMARY: Tamtron’s fortunes look much brighter with its acquisition by IMPAC Medical Systems, Inc., a healthcare information vendor with existing products for radiation oncology, medical oncology, and urology. IMPAC’s strategy is to create a “total solution” for oncology. That…
CURRENT ISSUE
Volume XXXI, No. 5 – April 8, 2024
The fragmentation of consumer markets is reflected in clinical lab services, and The Dark Report examines this trend and how it will impact labs in the coming years. Also, The Dark Report notes that the FDA has issued a controversial memo to reclassify many high-risk IVD assays.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized